There was a reference to
gene therapy and Gaucher Type 3 (GB3) pasted here by poof.
I don't know what poof is trying to do because the news is hardly helpful to Bioasis. I've been posting for ten years that Bioasis was missing the commercial window for LSD enzyme replacement therapies (ERT) due to the eventual replacement of ERTs by gene therapies.
It's striking in the news release that the patient's parents no longer have to get up at all hours of the night to treat their child and that ERT has been discontinued, meaning, no revenue for the pharma that was supplying the ERT. That's the future.
Although there is remaining commercial value in enzyme replacement therapies, the number of years of value is dropping and may drop to insignificance in the mid term.
But the big question for me has been why Bioasis and poof have been ignoring the huge value of brain tumours, neuroinflammation, and neurodegenerative diseases while pumping EGF, Hunter syndrome and Gaucher.
To me it means that poof and Bioasis have a common purpose of diminishing xB3's value in Bioasis's hands compared to its value in somebody else's hands, and that is very suspicious.
jd